In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celltech's New Wherewithal

Executive Summary

Britain's original biotech company, Celltech Group PLC, has lately made some strategic moves that make it the biggest biotech firm in all of Europe. The firm has been acquiring discovery, regulatory and marketing assets that will, it hopes, allow it to keep more of the value of its own antibody-based products. Celltech was able to do its acquisitions inexpensively, for stock, because the firms it bought were in trouble and poorly valued by the market. Their assets bring Celltech more potential than it has ever had. Big Pharma partnerships are still an option, but not a necessity. Celltech's challenge going forward is to integrate the new businesses, so they work well together. Even analysts clearly bullish on the company acknowledge the difficulty of the tasks awaiting management. Celltech, now in the spotlight as Europe's biggest biotech firm, possesses size and seniority. But neither will make it a market leader. Celltech must now successfully execute on tasks it has never before attempted.

You may also be interested in...

Global ‘Fair Access’ Coronavirus Vaccine Fund Launched, AZ Doubles Output Target

Pharma is looking to GAVI to oversee a fair distribution and avoid ‘vaccine nationalism’ – but countries can still sign bilateral deals with companies.

FDA Details Alternatives For COVID-19 Test Supplies

The US agency has released a document explaining what COVID-19 testing supplies may be substituted.

Curecumin Piques US Consumers’ Interest; UK Curiosity Grows For Omega-3, Survey Shows

Marketing consultant Buzzback surveyed 800 consumers in March, prior to novel coronavirus shutdowns in the two countries, to identify ingredients that offer opportunities for brands in health care, wellness and skin care.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts